Impact of cross-irradiation on single time-point dosimetry in 177Lu-PSMA therapy

被引：0
|
作者：
Vergnaud, L. [1 ]
Badel, J. [2 ]
Giraudet, A. [2 ]
Sarrut, D. [1 ]
机构：
[1] CREATIS Lab, Villeurbanne, France
[2] Ctr Leon Berard, Lyon, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0930
引用
收藏
页码：S804 / S804
页数：1
相关论文
共 50 条
  • [41] Radiation Dosimetry of 177Lu-PSMA; Results from a prospective clinical trial utilising automated voxelized dosimetry and comparison with PSMA PET/CT
    Violet, J. A.
    Jackson, P. A.
    Scalzo, M.
    Sandhu, S.
    Eu, P.
    Hicks, R. J.
    Hofman, M. S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S415 - S416
  • [42] Evaluating single point measurement for dosimetry in 177Lu-DOTATATE therapy
    Svensson, J.
    Hermann, R.
    Ryden, T.
    Hagmarker, L.
    Bernhardt, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S590 - S590
  • [43] Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
    Michalski, Kerstin
    Klein, Claudius
    Brueggemann, Tonio
    Meyer, Philipp T.
    Jilg, Cordula Annette
    Ruf, Juri
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1741 - 1746
  • [44] PBPK Model Based Voxel-wise Prediction of Posttherapy Dosimetry for 177Lu-PSMA I&T Therapy
    Xue, S.
    Gafita, A.
    Drobnjakovic, M.
    Zhao, Y.
    Birindelli, G.
    Afshar-Oromieh, A.
    Eiber, M.
    Rominger, A.
    Shi, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S345 - S346
  • [45] Pre- or Post-Chemotherapy: Effect of 177Lu-PSMA Radioligand Therapy on PSMA Expression
    Yadav, Surekha
    Heath, Courtney Lawhn
    Juarez, Roxanna
    De Kouchkovsky, Ivan
    Aggarwal, Rahul
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [46] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [47] Evaluation of the contamination risk during 177Lu-PSMA therapy of advanced prostate cancer
    Brosch-Lenz, Julia
    Nekolla, Stephan
    Tischendorf, Luisa
    Allmann, Jakob
    Weber, Wolfgang
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [48] Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid
    Simsek, Duygu Has
    Kuyumcu, Serkan
    Agaoglu, Fulya Yaman
    Unal, Seher Nilgun
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) : 764 - 766
  • [49] Comparison of 68Ga-PSMA and 177Lu-PSMA Total Metabolic Tumor Volume (TMTV) variations for monitoring metastatic castration-resistant prostate cancer in 177Lu-PSMA therapy.
    Boursier, C.
    Zaragori, T.
    Kunsch, J.
    Olivier, P.
    Claudin, M.
    Marie, P.
    Bros, M.
    Bordonne, M.
    Verger, A.
    Karcher, G.
    Imbert, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S361 - S362
  • [50] Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan, Farnaz
    Aryana, Kamran
    Askari, Emran
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E480 - E482
12345